Print

Print


Two copies of G2019S Parkinson's gene mutation doesn't lead to more severe
disease
No observable differences between homozygous and heterzygous state
A group of Parkinson's disease researchers concluded there are no observable
differences between those who have two copies of the most common mutation of
the recently discovered LRRK2 gene and those who have only one copy. Their
study will be published in the September edition of the Archives of
Neurology.
In most diseases with a genetic cause or component, two copies of a bad gene
lead to more severe visible manifestation of the disease. Researchers
expected to see worse symptoms, the disease start earlier in life and a
shorter life span for those with two copies of the LRRK2 gene with the
G2019S mutation. "That proved not to be the case," says Mayo Clinic
neurologist Zbigniew Wszolek, M.D.
Wszolek formed an international consortium that compared the clinical
features of Parkinson's disease in the two groups. "It's puzzling," he says.
"More studies are needed. More patients need to be identified and,
hopefully, more basic science research is going to be performed to find out
why."
The G2019S mutation is the most common of the 20 identified LRRK2
disease-causing mutations. There are six known genes that cause familial
Parkinson's disease, but only one, the G2019S mutation of the LRRK2 gene,
has been associated with previously unexplained cases of Parkinson's
disease. Wszolek and his colleagues hope that studying the ways in which
these genes cause disease, especially the G2019S mutation, will lead to
improved treatments and even a cure. "We are all united by the common drive
to learn more about this disease, to help the people with this illness and
to bring us closer to curative treatments," Wszolek says. "And this may be a
step in that direction."
By pooling their studies from around the globe, Wszolek and his colleagues
found 26 people with the G2019S mutation in both copies of their LRRK2
gene--one inherited from the mother and the other from the father.
Interestingly, three patients with the dual mutation exhibited no clinical
signs of Parkinson's disease, an indication that the gene has incomplete
penetrance.
This concept means having the gene mutation alone does not lead to
developing severe symptoms or even developing any signs of the disease 100
percent of the time. "One may need some additional factors, either genetic
or environmental, which work either to produce the disease or to protect one
from developing it," Wszolek says.
This latest finding supports the theory many hold that the majority of
Parkinson's disease cases may only be explained by the interaction of a
number of genes or a genetic and environmental interaction.
Wszolek and his colleagues found all patients in their study, whether they
had one or two G2019S mutations, had asymmetric onset of symptoms, most
often tremor, no male or female preponderance, and both groups had a similar
range in the age in which symptoms began.
In 2004 Wszolek was one of the researchers who discovered the LRRK2 gene
caused parkinsonism. He was also part of the team that discovered the G2019S
mutation causes parkinsonism in several North American and European
families. That was the first time a genetic cause had been associated with
typical, late-onset Parkinson's disease.
###

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn